Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).
Robert L. Ferris(University of Pittsburgh), Barbara Burtness(Yale University), Eduardo Méndez(University of Washington Medical Center), Yael Flamand(Dana-Farber Cancer Institute), Harry Quon(Johns Hopkins University), Wayne M. Koch(Johns Hopkins University), Nabil F. Saba(Emory University), Joaquín J. García(Mayo Clinic), Ranee Mehra(University of Maryland, Baltimore), R. Bryan Bell(Takara (United States)), Umamaheswar Duvvuri(City University of New York), Giovana R. Thomas(National Institutes of Health), Bert W. O’Malley(Baylor College of Medicine), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Miriam N. Lango(Fox Chase Cancer Center), Shuli Li(Unknown), Gregory S. Weinstein(University of Pennsylvania), Michael E. Kupferman(The University of Texas MD Anderson Cancer Center), Enver Özer(The Ohio State University Wexner Medical Center), Christine H. Chung(Moffitt Cancer Center)
Cited by 101
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k